Recent studies have shown that HSP90 forms a BCL6 complex and inhibits HSP90 with the drug PU-H71, a purine scaffold HSP90 inhibitor destabilizes BCL6 and selectively destroys in vitro and in vivo BCL6-positive DLBCL cells [73, 185]. This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.